Navigation Links
Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
Date:4/15/2008

Sciences of the United States of America (PNAS) in the edition published on April 15, 2008.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future fo
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. DAHANCA Initiates Head and Neck Cancer Study With Genmabs HuMax-EGFr
2. Bionomics Achieves US$1 Million Milestone Payment from Genmab
3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
4. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
5. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
6. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
7. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
8. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
9. Female Health Company Receives Brazilian Order: Four Million FC Female Condoms
10. The Pittsburgh Life Sciences Greenhouse Relocates Therapeutics Company to Pittsburgh
11. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Dec. 14 In response to an ... 2009, in which the Agency recommended that healthcare ... (SS1) sterile processing system, hospitals throughout the U.S. ... alternatives to that product. According to the FDA, ... SS1 that may affect the safety or the ...
(Date:12/14/2009)... Dec. 14 The board of directors of ... today declared a dividend for the first quarter of ... ,, The dividend is payable March 10, ... business on ,, February 12, 2010. ,, Lilly, ... of pharmaceutical products by applying the latest research from ...
(Date:12/14/2009)... Zargis Medical Corp., a majority-owned subsidiary of Speedus ... from Siemens Corporate Research (NYSE: SI ... its award-winning Zargis Cardioscan(TM) system on Amazon.com, America,s ... Bluetooth®-enabled electronic stethoscope were jointly named Popular ... the Year." Cardioscan is the world,s first ...
Breaking Medicine Technology:ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 3Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2Onyx Pharmaceuticals to Present at the Credit Suisse 18th Annual Healthcare Conference 14723 1Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 1Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 2Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 3Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 4Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 5Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 6Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 7Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 8Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 9Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 10Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 11Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 12Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 13Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 14Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 15Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 16Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 17Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 18Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 19NeoStem Inc Names Edward Geehr M D to Board of Directors 3B Biotechnology Executive Brings Scientific and Business Experience in Global Operations 5991 1NeoStem Inc Names Edward Geehr M D to Board of Directors 3B Biotechnology Executive Brings Scientific and Business Experience in Global Operations 5991 2NeoStem Inc Names Edward Geehr M D to Board of Directors 3B Biotechnology Executive Brings Scientific and Business Experience in Global Operations 5991 3
... Pa., May 30 Wyeth,Pharmaceuticals, a division ... announced the,initiation of the INTORACT (INvestigation of ... randomized, open-label, phase 3b,study comparing TORISEL(R) (temsirolimus) ... first-line treatment of patients,with advanced renal cell ...
... of safety and tolerability, as well ... trials -, ROCKVILLE, Md., May 30 Human ... it has initiated dosing in a Phase,1 clinical trial ... IAP,inhibitor, HGS1029, as monotherapy in patients with advanced solid ...
Other Medicine Technology:Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 2Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 3Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 4Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 5Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 6Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 2Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 3Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 4
(Date:12/14/2009)... ,, NEW YORK, Dec. 14 /PRNewswire-USNewswire/ ... study (MTF) -- the largest survey on teen drug ... -- underscores that teens, intentional abuse of prescription (Rx) ... for concern, with an alarming number of young people ... ,, Teen Abuse of Medication Continues to ...
(Date:12/14/2009)... The Hemophilia Federation of America (HFA) ... involving the Teamsters Local 929 and the American ... blood system depends on skilled workers to provide ... distilled into products such as clotting factor for ... ,, The Division of Blood Services at ...
(Date:12/14/2009)... benefited men whose disease had been treated, hadn,t spread, ... Exercise appears to reduce the risk of death in ... which began in January 1986, included 668 men who,d ... III colon cancer that had not spread (nonmetastatic cancer). ... asked them about any new cancer and disease diagnoses, ...
(Date:12/14/2009)... may also offer some protection, study finds, , , MONDAY, ... people who can,t start their morning without a cup ... decrease the risk of developing type 2 diabetes. ... also found the more coffee you drink, the lower ... associated with a 7 percent reduction in the risk ...
(Date:12/14/2009)... poorly treated and highly stigmatized, according to psychiatrists ... M.D., Ph.D. So these Washington University physicians have ... In "Demystifying Psychiatry," Zorumski and Rubin, who have ... patients and helping patient families, say some of ... result from a lack of understanding psychiatry and ...
Breaking Medicine News(10 mins):Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:HFA Voices Blood Safety Concerns 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Coffee, Tea Might Stave Off Diabetes 2Health News:Coffee, Tea Might Stave Off Diabetes 3Health News:Book demystifies psychiatry for the general public 2Health News:Book demystifies psychiatry for the general public 3
... the June 1 issue of the Journal of Clinical Investigation, ... Center shows that a key inflammatory regulator , a known ... stroke and other brain injuries, seems to do the opposite ... of clumps of material known as plaques that are a ...
... Human Genome Research Institute (NHGRI), part of the National ... will be tested as the first treatment for people ... degenerative muscle disease. In an unexpected finding, the research ... certain kidney disorders. ,The scientists, led by ...
... been clear that smoking causes cancer, but new research shows ... smokes . ,Canadian researchers have demonstrated in mice ... sperm cells, alterations that could potentially be inherited by offspring. ... 1 issue of Cancer Research, a journal of the American ...
... in Delhi Saturday, leaving millions of residents sweating it out ... ,According to the India Meteorological Department (IMD), the ... three degrees above the normal level, and a minimum of ... of 42.7 degrees in May 15, the hottest day of ...
... defeat for the ruling conservatives in Australian federal elections, Prime ... as a tough man , who would do anything to ... had kicked off a huge controversy with similar comments following ... state of Victoria had more than quadrupled in the past ...
... Haven, Conn. Yale Cancer Center is proud to announce the ... WNPR Connecticut Public Radio. Beginning on National Cancer Survivors Day ... to 6:30 p.m. on Sunday evenings and feature the latest ... and Ken Miller, M.D. , ,Cancer Answers is ...
Other Medicine News:Health News:Brain Inflammation A Friend for Alzheimer's Patients 2Health News:Brain Inflammation A Friend for Alzheimer's Patients 3Health News:Mouse Model Points to Strategy for Treating Rare Muscle Disease & Kidney Disorders 2Health News:Mouse Model Points to Strategy for Treating Rare Muscle Disease & Kidney Disorders 3Health News:Cigarette Smoke Alters DNA in Sperm, Genetic Damage Could Pass to Offspring 2Health News:Australian PM Wants to Prevent Entry of HIV Positive and Leprosy Affected People 2Health News:Yale Cancer Center Answers: A New Weekly Radio Progam on WNPR 2
... Excel Care ES bed is especially designed ... empowered, while protecting the caregivers who manage them. ... the most routine tasks pulling up in ... to caregivers and disheartening for patients. Excel Care ...
... Prefilled 28%-100% FIO 2 500ML 0.45% Sodium ... provide unmatched performance and ease of use. You ... from 28% to 100% FIO 2 . We ... for inhalation, USP; 0.45% sodium chloride inhalation, USP; ...
... 28%-100% FIO 2 1000ML 0.9% Sodium Chloride ... provide unmatched performance and ease of use. You ... from 28% to 100% FIO 2 . We ... for inhalation, USP; 0.45% sodium chloride inhalation, USP; ...
Respirgard II Nebulizer System with Acorn II Nebulizer, 7' (2 m) supply tubing, universal "antidrool" tee, mouthpiece, 6" (15 cm) aerosol tube, wye, one-way valve and expiratory filter...
Medicine Products: